Real-world effectiveness of immune checkpoint inhibitors and BRAF/ MEK inhibitors among veteran patients with cutaneous melanoma

被引：0
|
作者：
Kim, Daniel Y. [1 ,2 ]
Swetter, Susan M. [3 ,4 ]
Huhmann, Linden [5 ]
Dizon, Matthew P. [4 ,6 ]
Ferguson, Jacqueline M. [6 ]
Osborne, Thomas F. [2 ,7 ,8 ]
Spence, Allyson C. [9 ]
Ziad, Amina [1 ,2 ]
Fillmore, Nathanael [1 ,5 ,10 ,11 ]
Hartman, Rebecca I. [1 ,2 ,12 ]
机构：
[1] Harvard Med Sch, Boston, MA USA
[2] Brigham & Womens Hosp, Dept Dermatol, 221 Longwood Ave, Boston, MA 02115 USA
[3] Stanford Univ, Med Ctr, Dept Dermatol, Palo Alto, CA USA
[4] Vet Affairs Palo Alto Hlth Care Syst, Dermatol Serv, Palo Alto, CA USA
[5] Vet Affairs Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA USA
[6] Vet Affairs Palo Alto Hlth Care Syst, Ctr Innovat Implementat, Menlo Pk, CA USA
[7] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA
[8] Stanford Univ, Sch Med, Dept Radiol, Palo Alto, CA USA
[9] Stanford Univ, Dept Med Oncol, Med Ctr, Palo Alto, CA USA
[10] Dept Med, Vet Affairs Boston Healthcare Syst, Boston, MA USA
[11] Dana Farber Canc Inst, Boston, MA USA
[12] VA Integrated Serv Network 1 VISN 1, Dermatol Sect, Jamaica Plain, MA USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2024年 / 90卷 / 03期
关键词：
adjuvant; BRAF; cutaneous; cobimeti-; nib; dabrafenib; ICI; immune checkpoint inhib- itors; ipilimumab; MEK; melanoma; metastatic; nivolumab; pembrolizumab; real-world; stage III; stage IV; systemic; targeted therapies; VA; vemur-; afenib; veteran;
D O I：
10.1016/j.jaad.2023.10.051
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
[No abstract available]
引用
收藏
页码：620 / 623
页数：4
相关论文
共 50 条
  • [1] Uveitis associated with immune checkpoint inhibitors or BRAF/MEK inhibitors in patients with malignant melanoma
    Sada, Ikuyo
    Harada, Yosuke
    Hiyama, Tomona
    Mizukami, Mina
    Kan, Takanobu
    Kawai, Mikio
    Kiuchi, Yoshiaki
    MELANOMA RESEARCH, 2023, 33 (06) : 539 - 546
  • [2] Cardiotoxicity in metastatic melanoma patients treated with BRAF and MEK inhibitors in a real-world setting
    Pedersen, Sidsel
    Larsen, Kirstine Ostenfeld
    Christensen, Alex Horby
    Svane, Inge Marie
    Zerahn, Bo
    Ellebaek, Eva
    ACTA ONCOLOGICA, 2022, 61 (01) : 45 - 51
  • [3] The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors
    Julia Lai-Kwon
    Chloe Khoo
    Serigne Lo
    Donna Milne
    Mustafa Mohamed
    Jeanette Raleigh
    Kortnye Smith
    Karolina Lisy
    Shahneen Sandhu
    Michael Jefford
    Journal of Cancer Survivorship, 2019, 13 : 503 - 511
  • [4] The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors
    Lai-Kwon, Julia
    Khoo, Chloe
    Lo, Serigne
    Milne, Donna
    Mohamed, Mustafa
    Raleigh, Jeanette
    Smith, Kortnye
    Lisy, Karolina
    Sandhu, Shahneen
    Jefford, Michael
    JOURNAL OF CANCER SURVIVORSHIP, 2019, 13 (04) : 503 - 511
  • [5] Real-world impact of immune checkpoint inhibitors in metastatic uveal melanoma
    Bol, K. F.
    Ellebaek, E.
    Donia, M.
    Schmidt, H.
    Bastholt, L.
    Kiilgaard, J. F.
    Svane, I-M.
    ANNALS OF ONCOLOGY, 2019, 30 : 539 - 539
  • [6] Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma
    Bol, Kalijn Fredrike
    Ellebaek, Eva
    Hoejberg, Lise
    Bagger, Mette Marie
    Larsen, Mathilde Skaarup
    Klausen, Tobias Wirenfeldt
    Kohler, Ulrich Heide
    Schmidt, Henrik
    Bastholt, Lars
    Kiilgaard, Jens Folke
    Donia, Marco
    Svane, Inge Marie
    CANCERS, 2019, 11 (10)
  • [7] Utilization of real-world data to assess the effectiveness of immune checkpoint inhibitors (ICIs) in elderly patients with metastatic melanoma
    Ernst, D. S.
    McConkey, H.
    Liu, L.
    Butler, M. O.
    Petrella, T.
    Baetz, T.
    Koneru, R.
    Song, X.
    Cheng, T.
    Smylie, M. G.
    Rajagopal, S.
    Mihalcioiu, C.
    Gwadry-Sridhar, F.
    ANNALS OF ONCOLOGY, 2019, 30 : 553 - 553
  • [8] Sarcoidosis related to checkpoint and BRAF/MEK inhibitors in melanoma
    Rubio-Rivas, Manuel
    Moreira, Catarina
    Marcoval, J.
    AUTOIMMUNITY REVIEWS, 2020, 19 (08)
  • [9] BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience
    Rihawi, Karim
    Giannarelli, Diana
    Galetta, Domenico
    Delmonte, Angelo
    Giavarra, Marco
    Turci, Daniele
    Garassino, Marina
    Tiseo, Marcello
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (03) : E57 - E59
  • [10] Immune checkpoint and BRAF/MEK inhibitors: risk of uveitis
    Reactions Weekly, 2021, 1837 (1) : 10 - 10
12345